A retrospective analysis including a total of 4974 men revealed that the use of PDE5 inhibitors over a 7-year period was associated to a decreased incidence rate of prostate cancer among men with ED compared to men with ED of the same age and with similar risk factors who were not treated with these agents [221]. This evidence concerns the gene PDE5A and prostate cancer.